Physician profile
William Rose
NPI 1619995271
$2,318.51
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $446 · 2021: $685 · 2022: $259 · 2023: $53.32 · 2024: $63.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $443.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $412.38 | 2019-2022 | |
| Abbott Laboratories | $404.28 | 2019-2022 | |
| Medtronic, INC. | $294.90 | 2021-2022 | |
| Penumbra, INC. | $158.32 | 2020 | |
| Bard Peripheral Vascular, INC. | $126.87 | 2021 | |
| Getinge USA Sales, LLC | $85.31 | 2019 | |
| Endologix LLC | $77.79 | 2021 | |
| Artivion, INC. | $69.51 | 2022 | |
| Silk Road Medical, INC. | $63.91 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Mozarc Medical US LLC | $53.32 | 2023 | Palindrome |
| Angiodynamics, INC. | $43.06 | 2021 | |
| Pfizer INC. | $37.29 | 2020-2021 | |
| Organogenesis INC. | $23.90 | 2021 | |
| Boston Scientific Corporation | $16.72 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $7.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.